R&F Capital Advisors’s AbbVie ABBV Stock Holding History

R&F Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.35M	Buy	+20,683	New	+$1.3M	0.35%	60

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

R&F Capital Advisors's ABBV Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in AbbVie (ABBV) in Q1 2017: 20,683 shares worth $1.35M. The stake represents 0.35% of the portfolio and ranks #60 among its holdings.

1,727 funds tracked by Wall St. Rank hold ABBV as of Q1 2017.

R&F Capital Advisors held 20,683 shares of AbbVie worth $1.35M as of Q1 2017.
AbbVie was a new R&F Capital Advisors position in Q1 2017.
AbbVie made up 0.35% of R&F Capital Advisors's portfolio in Q1 2017, its #60 holding.
1,727 funds tracked by Wall St. Rank held AbbVie as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.